Cellular and molecular gastroenterology and hepatology · 2026
Mucosal-Associated Invariant T Cells Drive Bile Duct Inflammation.
СтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Nordhus Kathrine S, Zheng Fei, Berntsen Natalie L, Ramberg Oda Helgesen, Valestrand Laura, Øgaard Jonas, Chung Brian K, Jiang Xiaojun, Melum Espen
Аннотация
BACKGROUND & AIMS: Mucosal-associated invariant T cells recognize microbial-derived vitamin B metabolites presented by MHC I-related molecules. Because bile from patients with chronic biliary inflammation contain mucosal-associated invariant T antigens, we investigated whether intrabiliary mucosal-associated invariant T antigen exposure activates mucosal-associated invariant T cells and induce pathogenic biliary inflammation.
METHODS: Escherichia coli, phosphate-buffered saline, or the known mucosal-associated invariant T ligand 5-(2-oxopropylideneamino)-6-D-ribitylaminouracil were injected into bile ducts of mice with increased mucosal-associated invariant T cell frequencies (Mr1+ B6-MAITCAST and iVα19 Cα-/- Tg). Mice were monitored clinically and liver tissue analyzed after 1 to 14 days. Portal inflammation was assessed histologically. The immunophenotype of lymphocytes was determined by flow cytometry, and serum liver enzymes were measured. Hepatic mucosal-associated invariant T cell transcriptional profiles were analyzed by single-nucleus RNA sequencing.
RESULTS: Intrabiliary injection of E coli in iVα19 Cα-/- Tg mice caused cholangitis at day 2, elevated alanine aminotransferase, increased histologic grade of cholangitis, and portal accumulation of T-lymphocytes and macrophages. This coincided with marked hepatic mucosal-associated invariant T cell activation. Similar signs of experimental cholangitis were observed in mice containing 2% mucosal-associated invariant T cells (Mr1+ B6-MAITCAST). Selective activation with 5-(2-oxopropylideneamino)-6-D-ribitylaminouracil in iVα19 Cα-/- Tg mice confirmed the mucosal-associated invariant T specificity of the inflammatory response. In Mr1+ B6-MAITCAST mice, the mucosal-associated invariant T cell frequency was too low to induce biliary inflammation. Single-nucleus RNA sequencing of mucosal-associated invariant T cells from 5-(2-oxopropylideneamino)-6-D-ribitylaminouracil-injected iVα19 Cα-/- Tg mice demonstrated antigen-driven transcriptional reprogramming toward a mucosal-associated invariant T-17-skewed phenotype with enrichment of T cell receptor signaling pathways.
CONCLUSIONS: Mucosal-associated invariant T cells can drive pathogenic bile duct inflammation in vivo when locally exposed to antigens. These findings suggest that modulation of mucosal-associated invariant T-driven immune pathways may represent a therapeutic approach in inflammatory cholangiopathies.
METHODS: Escherichia coli, phosphate-buffered saline, or the known mucosal-associated invariant T ligand 5-(2-oxopropylideneamino)-6-D-ribitylaminouracil were injected into bile ducts of mice with increased mucosal-associated invariant T cell frequencies (Mr1+ B6-MAITCAST and iVα19 Cα-/- Tg). Mice were monitored clinically and liver tissue analyzed after 1 to 14 days. Portal inflammation was assessed histologically. The immunophenotype of lymphocytes was determined by flow cytometry, and serum liver enzymes were measured. Hepatic mucosal-associated invariant T cell transcriptional profiles were analyzed by single-nucleus RNA sequencing.
RESULTS: Intrabiliary injection of E coli in iVα19 Cα-/- Tg mice caused cholangitis at day 2, elevated alanine aminotransferase, increased histologic grade of cholangitis, and portal accumulation of T-lymphocytes and macrophages. This coincided with marked hepatic mucosal-associated invariant T cell activation. Similar signs of experimental cholangitis were observed in mice containing 2% mucosal-associated invariant T cells (Mr1+ B6-MAITCAST). Selective activation with 5-(2-oxopropylideneamino)-6-D-ribitylaminouracil in iVα19 Cα-/- Tg mice confirmed the mucosal-associated invariant T specificity of the inflammatory response. In Mr1+ B6-MAITCAST mice, the mucosal-associated invariant T cell frequency was too low to induce biliary inflammation. Single-nucleus RNA sequencing of mucosal-associated invariant T cells from 5-(2-oxopropylideneamino)-6-D-ribitylaminouracil-injected iVα19 Cα-/- Tg mice demonstrated antigen-driven transcriptional reprogramming toward a mucosal-associated invariant T-17-skewed phenotype with enrichment of T cell receptor signaling pathways.
CONCLUSIONS: Mucosal-associated invariant T cells can drive pathogenic bile duct inflammation in vivo when locally exposed to antigens. These findings suggest that modulation of mucosal-associated invariant T-driven immune pathways may represent a therapeutic approach in inflammatory cholangiopathies.